---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-102053"
form_type: "8-K"
ticker: "OGN"
cik: "0001821825"
company_name: "Organon & Co."
filed_at: "2024-09-23T23:59:59+00:00"
generated_at: "2026-05-31T02:29:42.713317+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Organon acquires Dermavant Sciences for up to $1.2B; VTAMA drug portfolio

## Summary
- Total consideration up to $1.2B: $175M upfront, $75M FDA milestone for atopic dermatitis, up to $950M commercial milestones.
- Dermavant shareholders also earn tiered royalty payments based on VTAMA net sales.
- Transaction expected to close Q4 2024, subject to HSR and other customary conditions.
- VTAMA (tapinarof) is approved for plaque psoriasis; milestone targets atopic dermatitis indication.

## SEC filing metadata
- accession: 0001104659-24-102053
- form_type: 8-K
- ticker: OGN
- cik: 0001821825
- company_name: Organon & Co.
- filed_at: 2024-09-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821825/000110465924102053/0001104659-24-102053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821825/000110465924102053/tm2424316d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-102053
- JSON: https://secwatch.observer/filing/0001104659-24-102053.json
- Plain text: https://secwatch.observer/filing/0001104659-24-102053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.